Press Releases
-
May 7, 2020ENGLEWOOD, CO / ACCESSWIRE / May 7, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the quarter ended March 31, 2020 on May 14, 2020, at 4:30 p.m. ET. The Company will review accomplishments from t...Apr 30, 2020500,000 Rapid Tests Cleared for Shipment to Company's Warehouse...Apr 27, 2020Company has Partnered with Sterling Medical to Finalize the Development of Cedars-Sinai-Developed 'Healight' Medical Device for Use in Patients with Coronavirus...Apr 24, 2020Company's Board of Directors Elects Not to Effect a Reverse Stock Split ...Apr 23, 2020ENGLEWOOD, CO / ACCESSWIRE / April 23, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced the signing of a definitive agreement (the "Agreement") with Singapore-based Biolidics, Limited (SGX: 8YY; "Biolidics") to exclusively distribute Biolidics' COVID-19 IgG/IgM ...Apr 21, 2020Nasally-Administered Natesto Testosterone Replacement Therapy Increases Serum Testosterone, Improves Hypogonadal Symptoms While Simultaneously Preserving Semen Parameters and Gonadotropin Hormones ...Apr 20, 2020Aytu BioScience Signs Exclusive Global License with Cedars-Sinai for Potential Coronavirus TreatmentCedars-Sinai-Developed ‘Healight' Medical Device Platform Technology Being Studied as a Potential First-in-Class COVID-19 Treatment...Apr 17, 2020Chinese Officials Confirm China Won't Restrict Exports of Medical Products Needed to Fight Coronavirus...Apr 16, 2020Independent clinical study demonstrates test accuracy of 98.0% and 94.1% for IgG and IgM, respectively, when using PCR-positive cases as true positives...Apr 15, 2020Company Places Third Purchase Order for One Million Tests...